Discovery Laboratories News

An executive realignment at Discovery Communications Inc. includes the departure of the Discovery Channel's president and general manager, John Ford.

Discovery Laboratories, Inc. announced today that, on December 2, 2009, the Company received a letter from The Nasdaq Stock Market indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5450 because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over the previous 30 consecutive ...

The Biotech Stock Mailbag is thinking about roast turkey and all the fixings, but first, let's answer some email.

Oprah Winfrey is ending her daytime show to focus her energy on a cable TV network she is creating in partnership with Discovery Communications Inc.

On 11/17/09, GeoVax announced that the FDA has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug application for the Company's therapeutic vaccine as a treatment for individuals already infected with HIV.

Discovery Laboratories, Inc. announced today that Thomas F. Miller, Ph.D., Senior Vice President of Corporate Development of Discovery Labs, will present an update on the Company's recent progress at the Lazard Capital Markets 6th Annual Healthcare Conference to be held in New York.

Discovery Communications Inc. - of which Denver's John Malone is a director and former chairman - reported higher third-quarter revenue but lower profits, in part from stock-compensation expenses.

Discovery Laboratories, Inc. will be hosting a conference call on Wednesday, November 4, 2009 at 4:00 PM EST.

Our analysts have issued complimentary analysis on the following six companies: La Jolla Pharmaceutical Co.

The SEC, which is bringing its enforcement action just three weeks after the scheme began, is seeking an emergency court order to enjoin the broker from further fraudulent activity.

Discovery Laboratories shares were sliding on above-average volume Friday, giving back gains earned earlier in the week on positive news for its experimental lung drug.

Discovery Laboratories shares soared 23% on heavy volume Wednesday after the company said it had established an approach with regulators to resolve questions about its lung drug Surfaxin.

Closing Bell: Market Indices retreat on manufacturing, employment, petroleum data Posted Sep 30th 2009 4:00PM by Douglas McIntyre Filed under: Major movement , CIT Group , S and P 500 , DJIA , NASDAQ The Dow Jones Industrial average jumped about 125 points on Monday but has given back about two-thirds of that gain through trading so far today.

TSTR inks distribution pact with AT&T. NKE continues evening gain that followed earnings beat.

25, 2009 Media Inquiries: Kevin Riley, 301-796-7349 kevin.riley.3@fda.hhs.org Consumer Inquiries: 888-DATE-FDA FDA Approves New Drug to Treat Psoriasis The U.S. Food and Drug Administration today approved Surfraxin , a biologic product with tremendous uses all over the spectrum of children to adults.

Stock Poisted to soar tomorrow morning at the open by over 1200%. Jim Cramer from the Street.com says with this tremendous with and praise from the FDA, DSCO will do what VVUS did to the 12th power.

Discovery Laboratories soared up 25% Monday amid a huge increase in trading volume.

From an anonymous poster regarding Discovery Labs : Hi VFC, What about DSCO? Made a big move today - been around a long time.

After a sit-down plan with the FDA regulators over the possibility of a limited trial, shares of Discovery Laboratories suddenly saw an upwards trend.

Discovery Laboratories Inc. has not given up on its Surfaxin drug candidate for respiratory distress syndrome, signaling Friday that it would propose a limited clinical trial to gain FDA approval.